My Cart

NKG2A

NKG2A Overview

English NameNK cell lectin-like receptor subfamily C member 1Approved Drugs0
Drugs in Clinical Trials6Target SynonymCD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
Highest Development StagePhase 3 Clinical
English NameNK cell lectin-like receptor subfamily C member 1
Target SynonymCD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
Approved Drugs0
Drugs in Clinical Trials6
Highest Development StagePhase 3 Clinical

NKG2A Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (2)Cynomolgus (1)Mouse (1)

  • Tag

    His Tag (3)Fc Tag (1)

  • Conjugate

    Unconjugated (4)

NKG2A Background

NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.

NKG2A Synonyms

NKG2A,CD159a,KLRC1,NK cell receptor A

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MonalizumabNNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201Phase 3 ClinicalNovo Nordisk A/SArthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
BMS-986315BMS-986315Phase 2 ClinicalBristol-Myers Squibb CompanyCarcinoma, Non-Small-Cell Lung; Solid tumours
Details
S-095029S-095029Phase 2 ClinicalInstitut De Recherches Internationales ServierCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms
Details
HY000102HY-0102; HY-000102Phase 2 ClinicalShanghai HyaMab Biotech Co LtdPancreatic Neoplasms; Solid tumours
Details
XB-628XB628Phase 1 ClinicalExelixis IncNeoplasms; Solid tumours
Details
BRY-805BRY805; BRY-805Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co LtdSolid tumours
Details

Product Reviews

  • A***n2024-09-17
    0People Like
    I used this recombinant protein to test function of a gRV transduction on iPS-derived cells. The product went into solution quickly during reconstitution and provided expected results from positive controls and testing samples. Signal was clear on a flow cytometry based readout using Streptavidin-Brilliant Violet 711. I used this at 5 ug at a concentration of 100 ug/mL on 50,000 total cells. No support was needed, as the provided data sheet and CoA are thorough and easy to follow. Very satisfied with my experience.
  • Overview
  • Product List
  • Product Reviews
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland